Reference health

Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis

https://doi.org/10.3899/jrheum.181127
CiteStamped reference-health badge
32/32 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 32 checked references that resolve
resolves10.1016/S0140-6736(08)61077-6
Polymyalgia rheumatica and giant-cell arteritis
resolves10.1136/annrheumdis-2011-200865
Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography
resolves10.1093/rheumatology/keu329
Large-vessel giant cell arteritis: a cohort study
resolves10.1097/MD.0000000000003851
18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis
resolves10.1056/NEJMra011913
Polymyalgia Rheumatica and Giant-Cell Arteritis
resolves10.1038/nrrheum.2012.97
Clinical features of polymyalgia rheumatica and giant cell arteritis
resolves10.3899/jrheum.141347
Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study
resolves10.1002/art.11388
Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes
resolves10.1002/art.1780330810
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
resolves10.1007/s00259-003-1144-y
Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI
resolves10.1002/art.22754
Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta‐analysis
resolves10.1056/NEJMoa1613849
Trial of Tocilizumab in Giant-Cell Arteritis
resolves10.1093/rheumatology/kev348
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study
resolves10.1097/MD.0000000000003524
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy
resolves10.1097/MD.0000000000000033
Relapses in Patients With Giant Cell Arteritis
resolves10.1097/MD.0b013e31821c4fad
Relapses and Recurrences in Giant Cell Arteritis
resolves10.3899/jrheum.120511
Giant Cell Arteritis with or without Aortitis at Diagnosis. A Retrospective Study of 22 Patients with Longterm Followup
resolves10.1002/art.1780400105
Disease patterns and tissue cytokine profiles in giant cell arteritis
resolves10.1161/CIRCULATIONAHA.109.872903
Th17 and Th1 T-Cell Responses in Giant Cell Arteritis
resolves10.1097/BOR.0b013e32833ee946
IFN-γ and IL-17: the two faces of T-cell pathology in giant cell arteritis
resolves10.1016/j.amjmed.2017.03.054
Giant-Cell Arteritis: Do We Treat Patients with Large-Vessel Involvement Differently?
resolves10.1016/j.jaut.2016.10.002
Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study
resolves10.1016/j.semarthrit.2013.10.009
Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis
resolves10.3899/jrheum.121150
Statin Use in Giant Cell Arteritis: A Retrospective Study
resolves10.1002/art.10071
Therapeutic effects of acetylsalicylic acid in giant cell arteritis
resolves10.1186/1741-7015-12-47
Is atherosclerosis an autoimmune disease?
resolves10.7326/M12-3046
Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis
resolves10.1097/01.md.0000101572.76273.60
Increased Prevalence of Severe Subclinical Atherosclerotic Findings in Long-Term Treated Rheumatoid Arthritis Patients Without Clinically Evident Atherosclerotic Disease
resolves10.1136/heartjnl-2017-311279
Association between chronic immune-mediated inflammatory diseases and cardiovascular risk
resolves10.1097/MD.0000000000007308
Cardiovascular disease in immune-mediated inflammatory diseases
resolves10.1136/heartjnl-2015-308514
Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases
resolves10.1002/art.23114
Atherosclerosis in patients with biopsy‐proven giant cell arteritis
The 1 reference without a DOI — listed, not checked
no DOI — not checkedTreatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.3899/jrheum.181127"><img src="https://citestamp.com/citestamped/10.3899/jrheum.181127/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.3899/jrheum.181127/badge.svg)](https://citestamp.com/citestamped/10.3899/jrheum.181127)